pharmaphorum
FEBRUARY 3, 2022
India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. While the regulatory framework for cannabinoid products remains fragmented and hard to navigate around the world, Germany has emerged as an early-mover.
Outsourcing Pharma
FEBRUARY 3, 2022
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
FEBRUARY 4, 2022
Tower Health Medical Group said in a statement that it learned of the allegations on Wednesday. After an investigation, the doctor’s employment was “terminated effective immediately.”.
Pharma Times
FEBRUARY 1, 2022
Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JANUARY 31, 2022
People with long-lasting symptoms of breathlessness after COVID-19 infection may have damage to their lungs that does not show up using routine diagnostic scans, according to a small UK study. The researchers from Oxford, Sheffield, Cardiff and Manchester universities used a new form of diagnostic that involves patients breathing in the inert gas xenon whilst undergoing an MRI scan, which allows them to gauge how well gases like oxygen are being transferred from the lungs to blood vessels.
Outsourcing Pharma
FEBRUARY 1, 2022
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 4, 2022
Pharma giant Sanofi continues to modernise with branding which reflects its commitment to social responsibility and sustainability
pharmaphorum
FEBRUARY 1, 2022
The new BA.2 subvariant of Omicron is around 50% more transmissible than the original BA.1 strain, and there is somewhat conflicting evidence on its ability to evade the protection from vaccines, according to new studies. BA.2 is now the dominant strain of the COVID-19 virus in Denmark, and scientists from the country’s Statens Serum Institute (SSI) have compared the two subvariants in more than 8,500 households including almost 18,000 people.
Outsourcing Pharma
JANUARY 31, 2022
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
Drug Channels
FEBRUARY 4, 2022
Today’s guest post comes from Jeff Berkowitz, CEO of advisory firm Real Endpoints. Jeff describes problems with Medicare copays that reduce adherence and persistence among seniors. He then describes RE Assist , Real Endpoints’ tech-enabled solution with key information on foundations for more than 30 diseases. To learn more about Medicare copayments and how the RE Assist solution helps patients, register to view Real Endpoints’ free webcast: Solving the Medicare Co-pay Dilemma.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
FEBRUARY 1, 2022
Ayvakyt receives a positive opinion from the CHMP for the treatment of adults with advanced systemic mastocytosis
pharmaphorum
JANUARY 30, 2022
2021 was a record year for investments in UK biotech companies, consolidating the country’s position as one of Europe’s top life science hubs and apparently shrugging off the effects of the pandemic and Brexit. All told, the sector raised £4.5 billion ($6 billion) in public and private financings during the year, almost two-third (60%) up on the previous year, with £1.3 billion coming from initial public offerings (IPOs) on both sides of the Atlantic.
Outsourcing Pharma
JANUARY 31, 2022
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimerâs drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
NY Times
FEBRUARY 1, 2022
Money from the tentative deal would go toward addiction and treatment and would be overseen by Native American tribal leaders.
Pharma Times
FEBRUARY 3, 2022
Significant landmark as NICE recommends AstraZeneca's chronic kidney disease treatment Forxiga
pharmaphorum
FEBRUARY 4, 2022
The approval of Novavax’ COVID-19 vaccine in Great Britain could help the country save a “considerable amount of money” if it is used in future booster campaigns, according to the former chair of UK Vaccine Taskforce. Dr Clive Dix said that Nuvaxovid has excellent clinical data and – as a it has good stability at fridge temperatures – could be easily rolled out with the flu vaccine next winter, and should “replace the need to buy more Pfizer and Moderna vaccine.” Nu
Outsourcing Pharma
FEBRUARY 1, 2022
During OSPâs exclusive February 23 webinar Rare and Orphan Diseases, leading expertswill lend their unique experience and expertise to the important topic.
Pharma in Brief
FEBRUARY 2, 2022
In a recently published discussion paper , an Advisory Panel (the Panel ) convened by the Canadian Agency for Drugs and Technologies in Health ( CADTH ) presents a proposed framework for a potential pan-Canadian formulary. The Panel is asking for feedback on the framework with an online questionnaire. The feedback will inform a stakeholder session in spring 2022 and the Panel’s final report.
Pharma Times
FEBRUARY 2, 2022
Boost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing
pharmaphorum
FEBRUARY 3, 2022
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit may not come until the last quarter of the year. The comments came despite rumours of another private equity bid for Sandoz, with Bloomberg saying it had got wind of a $25 billion combined bid from investment groups Blackstone and Carlyle, with others including Advent International, Hellman & Friedman and K
Outsourcing Pharma
FEBRUARY 3, 2022
The oncology centerâs Marie-JosÃe and Henry R. Kravis Cancer Ecosystems Project is intended to elevate the next generation of preclinical cancer research.
NY Times
FEBRUARY 2, 2022
Vuity, taken daily, promises clear vision for up to 10 hours. But does it work?
Pharma Times
FEBRUARY 4, 2022
Health and social care secretary will declare war on cancer with a decade-long plan to combat disease misery
pharmaphorum
FEBRUARY 3, 2022
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. We’ve all been there: stomach revolting, heart pounding, hands moist.
Outsourcing Pharma
JANUARY 31, 2022
The pharma firm has announced the agency has approved the companyâs investigational new drug application for its Phase II trial of pemvidutide for obesity.
Drug Patent Watch
FEBRUARY 4, 2022
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-six patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
FEBRUARY 2, 2022
Coalition urges reformation of EU-wide drug research and development to drive treatment optimisation
pharmaphorum
FEBRUARY 1, 2022
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. But what does it take to implement these innovations? Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
Pharma Mirror
FEBRUARY 4, 2022
Rockville, Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its role as a Data Coordinating Center on a team whose work has accelerated pediatric COVID-19 research through the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02).
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for SPIRIVA+RESPIMAT Spiriva Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are seven…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA RESPIMAT appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
JANUARY 31, 2022
Positive news for children aged six to 11 as Dupixent offers improved asthma treatment
pharmaphorum
FEBRUARY 4, 2022
Eli Lilly has backed away from plans to file Alzheimer’s drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen’s first-to-market Aduhelm has made going down the accelerated approval route all-but pointless. The company has planned to filed for speedy approval of donanemab based on the results of its TRAILBLZAR-ALZ study, in the hope of being allowed by the FDA to make the drug available to patients while its confirmatory TRAILBLAZER-AZ
Pharma Mirror
FEBRUARY 3, 2022
Everybody knows that life as a caretaker can get rough sometimes, but it also comes with its fair share of benefits. In this article, we aim to highlight some of the long-term benefits of wearing scrubs to work, day in and day out. Being youthful at heart and work Depending on the scrub policy you have at your place of work, charcoal grey scrubs can add a completely new layer to your professional attire.
Drug Patent Watch
FEBRUARY 3, 2022
Annual Drug Patent Expirations for RESTASIS Restasis is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There are ten patents protecting…. The post New patent for Allergan drug RESTASIS appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
FEBRUARY 3, 2022
Research collaboration between Parkinson’s UK and Domainex has potential to improve 140,000 lives
Expert insights. Personalized for you.
114 
Let's personalize your content